Bone Biologics Corp (BBLGW) Stock Price & Analysis

Bone Biologics Corp (BBLGW) rose 0.00% to USD 8 as of July 26, 2026 at 10:51 UTC, according to Nexqual real-time market data.

BBLGW last closed at USD 8; the session ranged USD 8–9.53 on volume of 401 shares. Market capitalization is —, with a 52-week range of USD 6.8–35.95 (NCM). Source: Nexqual, July 26, 2026 at 10:51 UTC.

Key Statistics (as of July 26, 2026 at 10:51 UTC)

Technical Analysis (BBLGW)

Nexqual's technical model rates BBLGW "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 10:51 UTC.

Analyst Ratings (BBLGW)

Wall Street analysts rate BBLGW "None", per Nexqual as of July 26, 2026 at 10:51 UTC.

Earnings (BBLGW)

Source: Nexqual, July 26, 2026 at 10:51 UTC.

Financials & Fundamentals (BBLGW)

Source: Nexqual, July 26, 2026 at 10:51 UTC.

Financial Health Score (BBLGW)

Nexqual rates Bone Biologics Corp's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 10:51 UTC.

Ownership (BBLGW)

Source: Nexqual, July 26, 2026 at 10:51 UTC.

Leadership (BBLGW)

Bone Biologics Corp is led by Jeffrey Frelick (age 59), CEO & President, per Nexqual as of July 26, 2026 at 10:51 UTC.

Major Backers & Investors (BBLGW)

Notable institutional backers of Bone Biologics Corp include Citadel, according to Nexqual as of July 26, 2026 at 10:51 UTC.

Active Investors

Source: Nexqual, July 26, 2026 at 10:51 UTC.

From Bone Biologics Corp's Latest SEC 10-K Filing (filed 2026-03-02)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition, rhNELL-1 was shown to be well tolerated and there were no findings of inflammation.   Proposed Initial Clinical Application   The NELL-1/DBM Fusion Device, NB1, will be indicated for spinal fusion procedures in skeletally mature patients with spinal degenerative disk disease ("DDD") at one level from L2-S1.
• We protect our proprietary technology through mechanisms including U.S. and foreign patent filings, trade secret protections, and collaboration agreements with domestic and international corporations, universities and research institutions.
• The study design was previously reviewed and agreed upon by the FDA's Division of Orthopedic Devices in a Pre-submission to support progression to a pivotal clinical trial in the United States.   Product Candidates   We have developed a stand-alone platform technology through significant laboratory and small and large animal research over more than 10 years to generate the current applications across broad fields of use.
• Our platform technology has been validated in sheep and non-human primate models to facilitate bone growth.

Partnerships

• Food and Drug Administration ("FDA") that NELL-1/DBM will be classified as a device/drug combination product that will require an FDA-approved pre-market approval ("PMA") application before it can be commercialized in the United States.   We were founded by University of California professors in collaboration with an Osaka University professor and a University of Southern California surgeon in 2004 as a privately held company with proprietary, patented platform technology.
• While the product is initially targeted at the lumbar spine fusion market, in keeping with our exclusive license agreement, we believe NELL-1's novel set of characteristics, target-specific mechanism of action, efficacy, safety and affordability position the product for application in a variety of procedures including:     UCLA's initial research was funded with approximately $18 million in resources from UCLA TDG and government grants.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 10:51 UTC. This page is informational and not investment advice.